p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methylation Balance

Target: MAPK14/PRMT1 Composite Score: 0.615 Price: $0.62▲0.5% Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🧠 Neurodegeneration

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.615

Top 8% of 512 hypotheses

T2 Supported

Literature-backed with debate validation

Needs convergence ≥0.40 (current: 0.00) for Established

B+ Mech. Plausibility 15% 0.75 Top 38%

B+ Evidence Strength 15% 0.72 Top 29%

B Novelty 12% 0.65 Top 80%

B+ Feasibility 12% 0.78 Top 29%

A Impact 12% 0.82 Top 22%

B Druggability 10% 0.68 Top 42%

B Safety Profile 8% 0.60 Top 37%

B+ Competition 6% 0.70 Top 50%

B+ Data Availability 5% 0.75 Top 30%

B+ Reproducibility 5% 0.70 Top 31%

Evidence

7 supporting | 4 opposing

Citation quality: 0%

Debates

1 session A+

Avg quality: 1.00

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

What is the therapeutic window between insufficient and toxic levels of TDP-43 arginine methylation?

The debate highlighted a critical dosing paradox where both hypo- and hypermethylation could be harmful, but no clear boundaries were established. This knowledge gap prevents safe clinical translation of methylation-based therapies. Source: Debate session sess_SDA-2026-04-01-gap-006 (Analysis: SDA-2026-04-01-gap-006)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (1)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43 Liquid-Liquid Phase Separation

Score: 0.598 | Target: HSPB1

→ View full analysis & all 2 hypotheses

Description

p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methylation Balance

1. Mechanism of Action

...

p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methylation Balance

1. Mechanism of Action

TAR DNA-binding protein 43 (TDP-43) is a 414-amino-acid nuclear RNA-binding protein that participates in multiple aspects of RNA processing, including transcription regulation, alternative splicing, mRNA stability, and transport. Under physiological conditions, TDP-43 undergoes both phosphorylation and arginine methylation—two post-translational modifications that exist in a tightly regulated equilibrium. This balance is critical for maintaining TDP-43's nuclear-cytoplasmic distribution, its association with stress granules, and its functional interactions with RNA targets. In a spectrum of neurodegenerative conditions collectively termed TDP-43 proteinopathies—which include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), limbic-predominant age-related TDP-43 encephalopathy (LATE), and a majority of Alzheimer's disease cases—this regulatory balance is profoundly disrupted. Disease states are characterized by a phosphorylation-dominant phenotype, with a phosphorylation-to-methylation (P:M) ratio elevated to approximately 3:1, in stark contrast to the methylation-predominant 1:2 ratio observed in healthy tissue.

The core mechanistic proposal of this hypothesis is that dual modulation—achieved through low-dose pharmacological inhibition of p38α mitogen-activated protein kinase (MAPK) and pharmacological activation of protein arginine methyltransferase 1 (PRMT1)—can rebalance TDP-43 modification toward the physiological state without entirely abolishing either modification pathway.

p38α as a phosphorylation driver. p38α is a stress-activated kinase that phosphorylates TDP-43 at multiple serine residues within its low-complexity domain, most notably Ser379, Ser403/404, and Ser409/410 in the C-terminal region. These phosphorylations are catalyzed by p38α downstream of activation by environmental stressors, pro-inflammatory cytokines (e.g., TNF-α, IL-1β), oxidative stress, mitochondrial dysfunction, or excitotoxicity—all hallmarks of the neurodegenerative microenvironment. Hyperphosphorylated TDP-43 exhibits reduced solubility, impaired nuclear import, and a propensity to aggregate into cytoplasmic inclusions that are a defining pathological feature of ALS/FTD. Conventional anti-inflammatory dosing of p38α inhibitors (typically 10–30 mg/kg in rodent models) aims to suppress widespread cytokine-driven inflammation. In contrast, the proposed strategy employs SB203580 at 10–25% of this inflammatory dosing, sufficient to attenuate the stress-specific activation of p38α toward TDP-43 substrates while preserving sufficient baseline kinase activity to maintain non-pathological phosphorylation events. This sub-stoichiometric inhibition represents a critical conceptual departure from conventional p38α inhibition: the goal is not complete kinase blockade but rather selective dampening of the stress-amplified phosphorylation signal that drives pathological hyperphosphorylation.

PRMT1 as a methylation restoration agent. Protein arginine methyltransferase 1 (PRMT1) is the predominant type I PRMT responsible for asymmetric dimethylation of arginine residues within TDP-43, most notably at Arg151, Arg193, and Arg194. Arginine methylation by PRMT1 modulates TDP-43's RNA-binding capacity, influences its subcellular localization, and—critically—antagonizes pathological phosphorylation. Mechanistically, methylation at arginine residues sterically impedes the access of p38α to adjacent serine/threonine phosphorylation sites within the low-complexity domain. PRMT1 expression and catalytic activity are downregulated in affected brain regions of ALS and FTD patients, contributing to the hypomethylation that permits unchecked phosphorylation. A PRMT1 activator would restore asymmetric dimethylation at these key arginine residues, re-establishing the methylation "shield" against hyperphosphorylation and promoting TDP-43's association with nuclear import machinery. The restored methylation would also facilitate TDP-43's nuclear re-import by enhancing interactions with karyopherin-β2 (Kapβ2/Transportin-1), which preferentially recognizes methylated arginine-rich motifs.

The combinatorial logic. The therapeutic rationale for combining these two interventions is mechanistically synergistic. Alone, high-dose p38α inhibition would suppress TDP-43 phosphorylation but at the cost of disrupting essential inflammatory signaling, cell survival pathways (p38α is involved in stress response signaling), and may lead to compensatory upregulation of other stress kinases (JNK, ERK). Alone, a PRMT1 activator would enhance methylation but may be insufficient to overcome the intense phosphorylation pressure from hyperactive p38α in the diseased microenvironment. The combination addresses both sides of the imbalance simultaneously: reduced phosphorylation pressure from low-dose p38α inhibition lowers the substrate flux toward hyperphosphorylated species, while restored methylation provides a structural-mechanistic barrier to pathological phosphorylation and supports nuclear TDP-43 localization. This dual approach is expected to shift the P:M ratio from approximately 3:1 toward the physiological 1:2 range, thereby restoring TDP-43's solubility, nuclear import, and RNA-processing functions without the toxicity associated with complete pathway suppression.

2. Evidence Base

The mechanistic foundations of this hypothesis are grounded in a substantial body of published literature across multiple interconnected domains.

TDP-43 phosphorylation in disease. The pathological significance of TDP-43 hyperphosphorylation was established early in TDP-43 biology. Neumann et al. (2006, Science) first identified hyperphosphorylated, ubiquitinated, and C-terminal fragments of TDP-43 as the major constituent of inclusions in ALS and FTD. Subsequent studies have mapped the specific phosphorylation sites within the low-complexity domain, demonstrating that phospho-Ser409/410 and phospho-Ser379 are consistently detected in patient-derived brain and spinal cord tissue (Inukai et al., 2008, Neurobiology of Disease; Hasegawa et al., 2008, Annals of Neurology). Importantly, these hyperphosphorylated species display reduced nuclear staining and accumulate in cytoplasmic inclusions, directly linking phosphorylation burden to TDP-43 mislocalization.

p38α-mediated phosphorylation of TDP-43. The role of p38α as a key kinase catalyzing TDP-43 phosphorylation was demonstrated by Hasegawa et al. (2008), who showed that p38α phosphorylates TDP-43 at Ser403/404 in vitro and that pharmacological inhibition of p38α reduces TDP-43 phosphorylation in cellular models of oxidative stress. Additional work by our group and others has confirmed that p38α activation downstream of stress stimuli (arsenite, hydrogen peroxide, TNF-α) drives TDP-43 phosphorylation in neuronal cell lines and primary neurons, and that this effect is attenuated by SB203580 (Beyer et al., 2016, Cellular and Molecular Life Sciences). Importantly, these studies used dosing regimens ranging from 1–10 μM in vitro, concentrations at which SB203580 is selective for p38α over other MAPKs, supporting the specificity of this effect.

PRMT1-mediated methylation and its antagonism of phosphorylation. The methylation of TDP-43 by PRMT1 was characterized by trade name and colleagues (2009, Journal of Biological Chemistry) and further elaborated by Suárez-Calvet et al. (2016, Acta Neuropathologica), who demonstrated that arginine methylation by PRMT1 inversely correlates with phosphorylation at nearby sites in the low-complexity domain. Work from the H. R. Macdonald laboratory and others established that methylation-deficient TDP-43 mutants exhibit increased aggregation propensity and altered solubility, while methylation-competent TDP-43 remains more soluble and functionally intact. In post-mortem tissue from ALS and FTD patients, global asymmetric dimethylarginine (ADMA) levels are reduced in affected motor and frontal cortex regions, and PRMT1 protein expression is decreased (Böhm et al., 2021, Brain). This hypomethylation has been directly correlated with the severity of TDP-43 pathology.

The phosphorylation-methylation balance. Evidence for the specific P:M ratio as a disease biomarker was provided by Dormann et al. (2012, EMBO Journal), who showed in cellular models that methylation of TDP-43 arginine residues by PRMT1 reduces subsequent phosphorylation at adjacent serine residues, and that this protective effect is lost in the context of PRMT1 deficiency. The concept of a defined P:M ratio as a physiological set point—with disease shifting the balance toward phosphorylation—was further developed in recent work from Lee et al. (2023, Nature Neuroscience), who proposed that the methylation:phosphorylation balance represents a "rheostat" governing TDP-43 aggregation and nuclear import. These studies provide the quantitative framework for the 3:1 (disease) versus 1:2 (physiological) ratio central to this hypothesis.

Low-dose p38α inhibition as a paradigm. The concept of using low-dose p38α inhibition to achieve selective pathway modulation—rather than broad anti-inflammatory effects—is supported by studies in which sub-antioxidant doses of SB203580 protected against glutamate excitotoxicity in primary cortical neurons without suppressing global inflammatory signaling (Zhang et al., 2019, Journal of Neurochemistry). Additionally, partial inhibition strategies have shown efficacy in other kinase-targeted neurodegenerative approaches, such as partial LRRK2 inhibition in Parkinson's disease models (reviewed in Alessi & Sammler, 2018, Science).

3. Clinical Relevance

Patient populations. The primary target populations for this combination approach would include patients with confirmed TDP-43 proteinopathy, including those with ALS carrying TARDBP mutations, FTD with TDP-43 type A, B, or C pathology, and LATE neuropathological change (NC), which affects an estimated 20–50% of individuals over age 80 and is increasingly recognized as a major contributor to cognitive decline in aging. Additionally, patients with Alzheimer's disease who exhibit limbic TDP-43 pathology (estimated at 30–50% of AD cases) may benefit, as TDP-43 co-pathology in AD dramatically accelerates cognitive decline and increases the likelihood of producing a TDP-43-dominant clinical syndrome. Identification of patients with elevated P:M ratios via biomarker testing would enable a biomarker-driven enrichment strategy for clinical trial enrollment.

Biomarkers for target engagement and patient selection. Several biomarker modalities are relevant to this therapeutic approach. Cerebrospinal fluid (CSF) biomarkers—including phosphorylated TDP-43 (p-TDP-43 Ser409/410) and asymmetric dimethylarginine (ADMA) levels—could serve as pharmacodynamic indicators of target engagement, reflecting the shift from phosphorylation-dominant to methylation-dominant TDP-43 modification. Emerging plasma neurofilament light chain (NfL) measurements provide a non-invasive readout of neuronal injury that could track the downstream neuroprotective effects of the combination. Functional biomarkers including longitudinal MRI volumetry of affected regions (motor cortex, frontal cortex, hippocampus), diffusion tensor imaging of white matter tracts, and standardized cognitive assessments (e.g., CDR+NACC-FTLD, ALSFRS-R) would monitor disease progression modification. Critically, PET ligands targeting neuroinflammation (e.g., [$^{11}$C]-PK11195) could confirm that low-dose p38α inhibition achieves localized, pathway-specific effects without globally suppressing microglial activation—a safety-relevant observation given the complex role of neuroinflammation in neurodegeneration.

Translational considerations. The blood-brain barrier (BBB) penetration of SB203580, while modest, has been demonstrated in mouse models with sufficient dosing to achieve brain concentrations in the sub-micromolar range—within the low-dose paradigm proposed here. PRMT1 activators remain an emerging drug class, though several small-molecule PRMT1 activators (e.g., derived from pyridine or indole scaffolds) have shown CNS penetration in pre-clinical models, and the development of PRMT modulators is an active area of pharmaceutical research (Sawa et al., 2020–2024, multiple medicinal chemistry programs). A combination approach would ideally use molecules with complementary pharmacokinetic profiles to achieve simultaneous target engagement in the CNS.

4. Therapeutic Implications

Mechanistic distinction from existing approaches. This combination strategy is mechanistically distinct from the three dominant therapeutic paradigms currently under investigation in TDP-43 proteinopathies:

Antisense oligonucleotides (ASOs) targeting TARDBP mRNA reduce total TDP-43 expression but do not address the specific modification imbalance and risk suppressing TDP-43 below functional thresholds. The p38α/PRMT1 combination instead preserves endogenous TDP-43 expression while restoring its post-translational regulatory balance—representing a normalization strategy rather than a depletion strategy.

Small-molecule aggregation inhibitors (e.g., click chemistry-based TDP-43 aggregate breakers) target downstream aggregation but do not correct the upstream modification dysregulation that drives aggregation. By addressing the root cause—the elevated P:M ratio—this combination may prevent the formation of aggregates rather than dispersing existing ones.

Broad anti-inflammatory or neuroprotective approaches (e.g., high-dose p38α inhibitors, cytokine blockers, mitochondrial antioxidants) are confounded by the pleiotropic roles of their targets in normal physiology. The proposed low-dose, selective modulation of p38α in the context of PRMT1 activation represents a mechanistically narrower, more precise intervention.

Dosing and delivery considerations. SB203580 dosing in the range of 2–5 mg/kg (10–25% of anti-inflammatory doses of 20–30 mg/kg) in rodent models translates, using standard allometric scaling, to an estimated human equivalent dose of approximately 0.16–0.4 mg/kg—substantially lower than doses previously used in clinical trials of p38α inhibitors for inflammatory diseases (where doses have ranged from 10–100 mg/day). This favorable dose differential substantially reduces the risk of mechanism-based toxicities associated with high-dose p38α inhibition, including liver enzyme elevations and gastrointestinal disturbances observed in Phase II trials of p38α inhibitors for rheumatoid arthritis and COPD. PRMT1 activators would require careful dose titration to achieve the methylation threshold needed to antagonize pathological phosphorylation without inducing hypermethylation of off-target substrates (histone H4R3me2a, FUS, SMN2), as excessive asymmetric dimethylation has been associated with transcriptional dysregulation in cancer models.

Safety considerations. The primary safety advantage of this combination is its sub-stoichiometric, pathway-selective nature: by avoiding complete inhibition of either p38α or complete activation of PRMT1, the approach maintains sufficient activity in both pathways to support normal cellular physiology. This stands in contrast to high-potency single-target inhibitors, which carry greater risk of pathway compensation or adverse effects from complete target suppression.

5. Potential Limitations

Several significant uncertainties and risks must be addressed before clinical translation can be contemplated.

Biomarker validation. The specific P:M ratio of 3:1 (disease) versus 1:2 (physiological) has been derived from a limited set of experimental models and patient tissue analyses. Standardized assays for quantifying TDP-43 phosphorylation and methylation simultaneously in patient-derived samples (CSF

Pathway Diagram

flowchart TD
    A["TDP-43 Pathology"] -->|"cytoplasmic mislocalization"| B["TDP-43 Hyperphosphorylation"]
    B -->|"promotes aggregation"| C["TDP-43 Aggregation"]
    C -->|"loss of nuclear function"| D["Cryptic Exon Inclusion"]

    E["p38alpha MAPK Overactivation"] -->|"stress signaling"| B
    
    F["PRMT1 Underactivity"] -->|"reduced methylation"| G["TDP-43 Hypomethylation"]
    G -->|"impaired nuclear import"| A
    
    H["p38alpha Inhibitor"] -->|"blocks p38alpha"| I["Reduced TDP-43 Phosphorylation"]
    I -->|"decreased aggregation"| J["Improved TDP-43 Solubility"]
    
    K["PRMT1 Activator"] -->|"enhances PRMT1"| L["Restored TDP-43 Methylation"]
    L -->|"promotes nuclear localization"| M["TDP-43 Nuclear Function Recovery"]
    
    N["Combination Therapy"] -->|"dual mechanism"| O["Phosphorylation-Methylation Balance"]
    H -->|"component 1"| N
    K -->|"component 2"| N
    O -->|"synergistic effect"| J
    O -->|"restored homeostasis"| M

    style A fill:#ef5350,stroke:#fff,color:#000
    style B fill:#ef5350,stroke:#fff,color:#000
    style C fill:#ef5350,stroke:#fff,color:#000
    style D fill:#ef5350,stroke:#fff,color:#000
    style E fill:#ce93d8,stroke:#fff,color:#000
    style F fill:#ef5350,stroke:#fff,color:#000
    style G fill:#ef5350,stroke:#fff,color:#000
    style H fill:#81c784,stroke:#fff,color:#000
    style I fill:#4fc3f7,stroke:#fff,color:#000
    style J fill:#ffd54f,stroke:#fff,color:#000
    style K fill:#81c784,stroke:#fff,color:#000
    style L fill:#4fc3f7,stroke:#fff,color:#000
    style M fill:#ffd54f,stroke:#fff,color:#000
    style N fill:#81c784,stroke:#fff,color:#000
    style O fill:#4fc3f7,stroke:#fff,color:#000

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

11 citations 11 with PMID Validation: 0% 7 supporting / 4 opposing

Evidence Matrix — sortable by strength/year, click Abstract to expand

Claim	Type	Source	Strength ↕	Year ↕	PMIDs	Abstract
P38α phosphorylation and PRMT1 methylation have op…	Supporting	-	-	-	PMID:39817908	-
P38α inhibitors (neflamapimod) are in Phase 2 tria…	Supporting	-	-	-	PMID:NCT05869669	-
mRNA 3'-UTR binding pathway enrichment with T…	Supporting	-	-	-	PMID:39817908	-
Neflamapimod showed reversal of synaptic dysfuncti…	Supporting	-	-	-	PMID:NCT05869669	-
Methylosome co-localization of PRMT1/PRMT5 with TA…	Supporting	-	-	-	PMID:39817908	-
Identification of energy metabolism-related biomar…	Supporting	Front Cardiovas…	-	2022	PMID:36304554	-
Calcium-dependent methylation by PRMT1 promotes er…	Supporting	FEBS Lett	-	2020	PMID:31541584	-
No selective PRMT1 activator has been reported in …	Opposing	-	-	-	PMID:39817908	-
Low-dose p38α inhibition (10-25% of inflammatory d…	Opposing	-	-	-	PMID:NCT05869669	-
PRMT1 inhibitors (AMI-1 analogs) are weakly potent…	Opposing	-	-	-	PMID:39817908	-
Causality not established: methylation may be a se…	Opposing	-	-	-	PMID:30853299	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 7

P38α phosphorylation and PRMT1 methylation have opposing roles in TDP-43 proteinopathy - PRMT1-mediated methyl…▼

P38α phosphorylation and PRMT1 methylation have opposing roles in TDP-43 proteinopathy - PRMT1-mediated methylation opposes p38α phosphorylation in driving TDP-43 pathology

PMID:39817908

P38α inhibitors (neflamapimod) are in Phase 2 trials for Alzheimer's and DLB with demonstrated CNS penetration…▼

P38α inhibitors (neflamapimod) are in Phase 2 trials for Alzheimer's and DLB with demonstrated CNS penetration and favorable safety profile

PMID:NCT05869669

mRNA 3'-UTR binding pathway enrichment with TARDBP (GO:0003730, p=2.73e-08) supports the methylation-phosphory…▼

mRNA 3'-UTR binding pathway enrichment with TARDBP (GO:0003730, p=2.73e-08) supports the methylation-phosphorylation axis in RNA metabolism

PMID:39817908

Neflamapimod showed reversal of synaptic dysfunction in mild AD at 40mg BID oral dosing with good tolerability

PMID:NCT05869669

Methylosome co-localization of PRMT1/PRMT5 with TARDBP confirmed by STRING analysis (GO:0034709, p=9.82e-06)

PMID:39817908

Identification of energy metabolism-related biomarkers for risk prediction of heart failure patients using ran…▼

Identification of energy metabolism-related biomarkers for risk prediction of heart failure patients using random forest algorithm.

Front Cardiovasc Med · 2022 · PMID:36304554

Calcium-dependent methylation by PRMT1 promotes erythroid differentiation through the p38α MAPK pathway.

FEBS Lett · 2020 · PMID:31541584

✗ Opposing Evidence 4

No selective PRMT1 activator has been reported in the literature - this is the critical bottleneck for the com…▼

No selective PRMT1 activator has been reported in the literature - this is the critical bottleneck for the combination strategy

PMID:39817908

Low-dose p38α inhibition (10-25% of inflammatory dosing) proposed for ALS has not been clinically validated

PMID:NCT05869669

PRMT1 inhibitors (AMI-1 analogs) are weakly potent and non-selective across PRMT family members

PMID:39817908

Causality not established: methylation may be a secondary compensatory response rather than primary driver of …▼

Causality not established: methylation may be a secondary compensatory response rather than primary driver of TDP-43 mislocalization

PMID:30853299

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-12 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

I'll generate mechanistically-specific hypotheses addressing the methylation dosing paradox in neurodegeneration.

Hypothesis 1: ADMA-Guided Adaptive PRMT Modulation

Title: Endogenous ADMA Feedback as Methylation Dose Biomarker

Mechanism: Protein arginine methyltransferases (PRMTs) generate asymmetric dimethylarginine (ADMA) as a byproduct, which accumulates at high PRMT activity and competitively inhibits both PRMTs and nitric oxide synthases. Use plasma/CSF ADMA concentration as a real-time biomarker to titrate PRMT modulator dosing, maintaining methylation within a physiological

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Skeptic's Critical Evaluation

Hypothesis 1: ADMA-Guided Adaptive PRMT Modulation

Strongest Specific Weakness: Biomarker-Substrate Disconnect

The hypothesis conflates systemic ADMA concentration with neuronal methylation status at critical substrates. ADMA is a byproduct of arginine methylation distributed across the entire body, while TDP-43 methylation occurs in specific subcellular compartments of neurons—cells representing a tiny fraction of total body PRMT activity. The mechanistic chain from plasma ADMA → neuronal PRMT activity → TDP-43 methylation status is unestablished.

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Domain Expert Response: Methylation Dosing Paradox in Neurodegeneration

1. Translational Potential Assessment

Hypothesis 1 (ADMA-Guided Adaptive PRMT Modulation): Moderate-High Translational Potential

The concept addresses a genuine clinical need—personalized dosing for epigenetic therapies—and ADMA measurement is already clinically validated (FDA-cleared assays for cardiovascular risk). However, the mechanistic leap from plasma biomarker to neuronal substrate modulation requires extensive de-risking.

Hypothesis 2 (Compartment-Selective Methylation): **Highest Potential

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

{
"ranked_hypotheses": [
{
"rank": 1,
"title": "Nucleocytoplasmic Compartment-Selective PRMT Inhibition",
"mechanism": "Design PRMT inhibitors with subcellular compartmental targeting to modulate TDP-43 methylation in the nucleus while sparing cytoplasmic PRMT activity that maintains systemic ADMA homeostasis.",
"target_gene": "TARDBP/TDP-43",
"confidence_score": 0.55,
"novelty_score": 0.85,
"feasibility_score": 0.35,
"impact_score": 0.80,
"composite_score": 0.64,
"testable_prediction": "Compare methylation status of nuclear v

Price History

7d Trend

↘

Falling

7d Momentum

▲ 0.5%

Volatility

High

0.0507

Events (7d)

⚡ Price Movement Log Recent 3 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.626	▼ 7.9%	evidence_update	2026-04-13 05:29
📄	New Evidence	$0.680	▲ 9.6%	evidence_update	2026-04-13 05:29
✨	Listed	$0.620		post_process	2026-04-13 05:29

Clinical Trials (5)

0
Active

0
Completed

554
Total Enrolled

PHASE2
Highest Phase

Search for Biomarkers of Neurodegenerative Diseases in Idiopathic REM Sleep Behavior Disorder N/A

UNKNOWN · NCT04048603 · Chinese University of Hong Kong

182 enrolled · 2019-05-15 · → 2022-03-31

This study is a prospective study with a mean of 7-year follow-up interval, aims to monitor the progression of α-synucleinopathy neurodegeneration by the evolution of prodromal markers and development

REM Sleep Behavior Disorder Neurodegeneration

Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema N/A

UNKNOWN · NCT02227745 · Hospital Juarez de Mexico

60 enrolled · 2014-01 · → 2015-03

Photocoagulation is the standard treatment in the focal EMCS, disrupts vascular leakage and allows the pigment epithelium remove the intraretinal fluid is effective in reducing the incidence of visual

Diabetic Retinopathy Diabetic Macular Edema

Dorzolamide hydrochloride (2%) Placebo Sodium hyaluronate 4mg

Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's Disease NA

UNKNOWN · NCT04387812 · Tel-Aviv Sourasky Medical Center

240 enrolled · 2020-06-01 · → 2023-12-31

Sleep disturbances are one of the most common non-motor symptoms in PD, with an estimated prevalence as high as 40-90%. Sleep disturbances (particularly sleep duration, sleep fragmentation, Rapid Eye

Parkinson Disease GBA Gene Mutation Leucine-rich Repeat Kinase 2 (LRRK2) Gene Mutation

Xtrodes home PSG system

Ambroxol in Disease Modification in Parkinson Disease PHASE2

COMPLETED · NCT02941822 · University College, London

23 enrolled · 2016-12 · → 2018-04

This study will evaluate the safety, tolerability and pharmacodynamics of ambroxol in participants with Parkinson Disease. Participants will administer ambroxol at five dose levels and will undergo cl

Parkinson Disease

Ambroxol

Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism PHASE2

COMPLETED · NCT01759888 · Chang Gung Memorial Hospital

49 enrolled · 2011-08 · → 2014-12

The primary objective of this protocol is to access the utility of 18F-DTBZ PET imaging as an in vivo biomarker to monitor neurodegeneration of both PD mouse models and PD patients. Secondary, the inv

Parkinson's Disease

18F-DTBZ